X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with GSK Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA GSK PHARMA NATCO PHARMA/
GSK PHARMA
 
P/E (TTM) x 27.5 66.0 41.6% View Chart
P/BV x 20.8 10.6 196.3% View Chart
Dividend Yield % 0.5 1.2 46.0%  

Financials

 NATCO PHARMA   GSK PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
GSK PHARMA
Mar-17
NATCO PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs8773,838 22.9%   
Low Rs4242,637 16.1%   
Sales per share (Unadj.) Rs223.4354.2 63.1%  
Earnings per share (Unadj.) Rs31.139.8 78.1%  
Cash flow per share (Unadj.) Rs40.342.9 93.9%  
Dividends per share (Unadj.) Rs5.0030.00 16.7%  
Dividend yield (eoy) %0.80.9 83.0%  
Book value per share (Unadj.) Rs219.5236.9 92.6%  
Shares outstanding (eoy) m33.0784.70 39.0%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.99.1 31.8%   
Avg P/E ratio x20.981.4 25.7%  
P/CF ratio (eoy) x16.175.5 21.4%  
Price / Book Value ratio x3.013.7 21.7%  
Dividend payout %16.175.4 21.3%   
Avg Mkt Cap Rs m21,504274,216 7.8%   
No. of employees `000NA4.7 0.0%   
Total wages/salary Rs m1,1284,830 23.3%   
Avg. sales/employee Rs ThNM6,387.0-  
Avg. wages/employee Rs ThNM1,028.3-  
Avg. net profit/employee Rs ThNM717.1-  
INCOME DATA
Net Sales Rs m7,38930,000 24.6%  
Other income Rs m167728 22.9%   
Total revenues Rs m7,55630,728 24.6%   
Gross profit Rs m1,7934,190 42.8%  
Depreciation Rs m304263 115.7%   
Interest Rs m3660-   
Profit before tax Rs m1,2904,655 27.7%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m3091,744 17.7%   
Profit after tax Rs m1,0273,368 30.5%  
Gross profit margin %24.314.0 173.8%  
Effective tax rate %23.937.5 63.9%   
Net profit margin %13.911.2 123.9%  
BALANCE SHEET DATA
Current assets Rs m3,68116,742 22.0%   
Current liabilities Rs m3,1237,202 43.4%   
Net working cap to sales %7.631.8 23.8%  
Current ratio x1.22.3 50.7%  
Inventory Days Days8952 172.7%  
Debtors Days Days5921 282.4%  
Net fixed assets Rs m7,6858,635 89.0%   
Share capital Rs m331847 39.0%   
"Free" reserves Rs m6,67019,222 34.7%   
Net worth Rs m7,25920,069 36.2%   
Long term debt Rs m95510 9,549.0%   
Total assets Rs m11,95730,038 39.8%  
Interest coverage x4.5NM-  
Debt to equity ratio x0.10 26,400.3%  
Sales to assets ratio x0.61.0 61.9%   
Return on assets %11.711.2 103.9%  
Return on equity %14.216.8 84.3%  
Return on capital %20.725.5 81.4%  
Exports to sales %39.40-   
Imports to sales %5.70-   
Exports (fob) Rs m2,908NA-   
Imports (cif) Rs m421NA-   
Fx inflow Rs m3,445528 652.5%   
Fx outflow Rs m7037,193 9.8%   
Net fx Rs m2,743-6,665 -41.1%   
CASH FLOW
From Operations Rs m1,4402,360 61.0%  
From Investments Rs m-1,0893,008 -36.2%  
From Financial Activity Rs m-353-5,108 6.9%  
Net Cashflow Rs m-1260 -0.6%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 50.7 2.9%  
Indian inst/Mut Fund % 7.8 10.2 76.9%  
FIIs % 16.6 23.8 69.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 15.4 168.8%  
Shareholders   25,395 102,036 24.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALEMBIC PHARMA  AJANTA PHARMA  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Dull End to the Trading Day; Metal & Auto Stocks Fall(Closing)

Indian share markets continued to trade range-bound in the afternoon session amid mixed international markets. At the closing bell, the BSE Sensex closed higher by 27 points.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Of Falling Real Estate Prices, Dr Arvind Panagariya and the Art of Continuing to Suck Up(Vivek Kaul's Diary)

Nov 13, 2017

Dr Panagariya claims real estate prices have fallen 25 per cent post demonetisation; the official data doesn't show anything like that.

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

When the Sherlock Holmes in Me Follows Super Investors...(The 5 Minute Wrapup)

Nov 11, 2017

This Super Investor has knack of spotting megatrends in India.

Why I am the Biggest India Equity Bull on Planet Earth!(The Honest Truth)

Nov 16, 2017

If you have a dream, dream big...about the level of BSE 30 index in 2050!

The Day Warren Buffett Lost All His Money(Smart Contrarian)

Nov 15, 2017

Buffett is still using the lessons he learnt that fateful day.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Nov 23, 2017 03:35 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - ABBOTT INDIA COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS